[2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]carbamic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: [2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]carbamic acid
• 英文别名: [2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]carbamic acid
• 化学式: C₁₄H₁₁N₃O₆
• 分子量: 317.25
• InChiKey: AQUGOXSICHUBOZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  133
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• [EN] TARGETED THERAPEUTICS<br/>[FR] THÉRAPEUTIQUE CIBLÉE
  申请人：SYNTA PHARMACEUTICALS CORP

  公开号：WO2015038649A1

  公开（公告）日：2015-03-19

  The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.

  本发明提供了包括与将效应子导向至感兴趣的生物靶点的结合基团共轭的药理化合物。同样，本发明提供了包括这些化合物的组合物、试剂盒和方法（例如治疗、诊断和成像）。这些化合物可以被描述为蛋白质相互作用结合基团-药物共轭（SDC-TRAP）化合物，其中包括蛋白质相互作用结合基团和效应子。例如，在针对治疗癌症的某些实施方式中，SDC-TRAP可以包括Hsp90抑制剂共轭到细胞毒性药剂作为效应子。
• [EN] PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS<br/>[FR] PROCÉDÉS DE PRÉPARATION DE COMPOSÉS ISOINDOLINE-1,3-DIONE
  申请人：CELGENE CORP

  公开号：WO2014018866A1

  公开（公告）日：2014-01-30

  Provided herein are processes for preparing an isoindoline- 1.3-dione compound, or an enantiomer or a mixture of enantiomers thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or polymorph thereof.

  本文提供了制备异吲哚啉-1,3-二酮化合物的过程，或其对映体或对映体的混合物；或其药用可接受的盐、溶剂化合物、水合物或多晶形式。
• TARGETED THERAPEUTICS HAVING AN HSP90 LIGAND AS BINDING MOIETY
  申请人：Madrigal Pharmaceuticals, Inc.

  公开号：EP3738594A1

  公开（公告）日：2020-11-18

  The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions and therapeutic methods including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety which is an Hsp90 ligand and an effector moiety. The therapeutic uses include the treatment of cancer, chronic bronchitis, asthma, and actinic keratosis.

  本发明提供的药理化合物包括与结合基团共轭的效应分子，该结合基团可将效应分子导向感兴趣的生物靶标。同样，本发明还提供了包括这些化合物的组合物和治疗方法。这些化合物可以被描述为蛋白质相互作用结合分子-药物共轭物（SDC-TRAP）化合物，其中包括一个蛋白质相互作用结合分子（Hsp90 配体）和一个效应分子。治疗用途包括治疗癌症、慢性支气管炎、哮喘和日光性角化病。
• 3-substituted piperidine-2, 6-diones and non-covalent complexes with albumin
  申请人：Zhuhai Beihai Biotech Co., Ltd.

  公开号：US10201617B2

  公开（公告）日：2019-02-12

  The present disclosure provides derivatives of 3-substituted piperidine-2, 6-diones, non-covalently bound complexes with serum albumin, pharmaceutical compositions of the same, and methods of use thereof. The non-covalently bound complexes are significantly more water-soluble than the parent compounds, and are useful for the treatment of a cancer, such as multiple myeloma.

  本公开提供了 3-取代哌啶-2，6-二酮的衍生物、与血清白蛋白的非共价结合复合物、其药物组合物及其使用方法。非共价结合复合物的水溶性明显高于母体化合物，可用于治疗癌症，如多发性骨髓瘤。
• Targeted therapeutics
  申请人：Madrigal Pharmaceuticals, Inc.

  公开号：US10828315B2

  公开（公告）日：2020-11-10

  The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.

  本发明提供的药理化合物包括与结合基团共轭的效应分子，该结合基团可将效应分子导向感兴趣的生物靶标。同样，本发明还提供了包括这些化合物的组合物、试剂盒和方法（如治疗、诊断和成像）。这些化合物可被描述为蛋白质相互作用结合分子-药物共轭物（SDC-TRAP）化合物，其中包括蛋白质相互作用结合分子和效应分子。例如，在某些用于治疗癌症的实施方案中，SDC-TRAP 可包括与细胞毒剂共轭的 Hsp90 抑制剂作为效应分子。